Role of monomeric amyloid-β in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies-Reference-Cited by-同舟云学术

Role of monomeric amyloid-β in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies

Published:2023-01 Issue: Volume:187 Page:106631
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Imbimbo Bruno P.,Ippati Stefania,Watling Mark,Imbimbo Camillo

Publisher

Elsevier BV

Subject

Pharmacology

Reference87 articles.

1. Plasma Aβ42 as a biomarker of prodromal alzheimer's disease progression in patients with amnestic mild cognitive impairment: evidence from the PharmaCog/E-ADNI study;Albani;J. Alzheimers Dis.,2019

2. Cerebrospinal fluid β-amyloid42 in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease;Andreasen;Arch. Neurol.,1999

3. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease;Arriagada;Neurology,1992

4. Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer’s disease treated with bapineuzumab: a historical, prospective secondary analysis;Arrighi;J. Neurol. Neurosurg. Psychiatry,2016

5. Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy;Bacskai;Nat. Med.,2001

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-amyloid immunotherapy in Alzheimer’s disease: The new dawn emerging from 179 clinical trials;Pharmacological Research;2024-10

2. A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Bioactive Peptides;Current Protein & Peptide Science;2024-09

3. A Study on the Effect of Executive Control Network Functional Connection on the Therapeutic Efficacy of Repetitive Transcranial Magnetic Stimulation in Alzheimer’s Disease;Journal of Alzheimer's Disease;2024-06-11

4. Recalibrating the Risk-Benefit Profiles of Lecanemab and Donanemab: Scales, Immunoreactivity, and Changes in Amyloid-β42;Journal of Alzheimer's Disease;2024-05-28

5. A turn for the worse: Aβ β-hairpins in Alzheimer’s disease;Bioorganic & Medicinal Chemistry;2024-05